Главная
Рынки
Графики и идеи
Алготрейдинг
Новости
Store
Брокеры
Скачать
Экономический календарь
Торговые сигналы
Вебтерминал
Нажмите
/
для поиска: @user, $symbol, ...
Поиск
Вход
Создать аккаунт
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRME
#2354
Prime Medicine, Inc. Common Stock
4.6
2
+7.94%
Сектор:
Базовая:
Валюта прибыли:
Дневной диапазон
Годовой диапазон
Дневное изменение
+7.94%
Месячное изменение
+6.21%
6-месячное изменение
+35.48%
Годовое изменение
+87.04%
Предыдущее закрытие
4.2
8
Open
4.6
2
Bid
Ask
Low
4.6
2
High
4.6
2
Объем
111
Рынки
Рынок акций США
Здравоохранение
PRME
Open full chart
Financials
Overview
Отчетность
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
97.25 M
119.94 M
131.16 M
—
Valuation ratios
Enterprise value
1.52 B
1.01 B
200.51 M
1.58 B
Price to earnings ratio
-4.19
-4.02
-1.77
-8.44
Price to sales ratio
—
4 743.4
116.1
359.19
Price to cash flow ratio
-4.51
-4.82
-2.82
-15.09
Price to book ratio
1.88
5.99
2.26
4.68
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
0.34
1.02
0.66
0.62
Return on equity %
0.39
1.49
1.28
1.94
Return on invested capital %
623.13
1 100.7
952.9
—
Gross margin %
—
100
100
400
Operating margin %
—
121.9 K
6 787.36
14.82 K
EBITDA margin %
—
—
—
—
Net margin %
—
117.94 K
6 566.61
14.35 K
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
11.1
2.53
5.58
20.52
Inventory turnover
—
—
—
—
Asset turnover
0
0
0.01
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
3.89
1.82
1.04
0.78
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
8.67
1.34
1.61
4.82
Net current asset value per share
8.75
1.57
1.79
5.42
Tangible book value per share
9.33
1.46
1.29
3.59
Working capital per share
7.96
0.95
1.47
4.35
Book value per share
9.33
1.46
1.29
3.59
Новости
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Prime Drink Group conclui primeira fase de captação por esforços restritos
Prime Drink Group completes first closing of private placement
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond
Prime Drink Group anuncia captação de até US$ 5 milhões por esforços restritos
Prime Drink Group announces private placement to raise up to $5 million
Goldman Sachs mantém classificação de biotecnologia em estágio inicial para ações da Prime Medicine
Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine appoints Matthew Hawryluk as chief business officer
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME)